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Problems of university-based scientists associated with
clinical trials
University faculty members who participate in clinical trials face a number of difficulties in
connection with this association. Publication opportunities are often limited, and individual
scholarship is difficult to express and evaluate within the context of a cooperative trial. Merit
increases, promotion, and the award of tenure will usually require evidence of scholarly
achievement outside the trial setting. For this reason, it seems inadvisable to recommend that a
young investigator devote a major portion of his scholarly and research time to such an activity.
A possible exception may be a full-time appointment for I to 2 years. Nonetheless, cooperative
clinical trials are an important investigative tool and they should continue to be associated with
academic centers. /f appropriate administrative arrangements can be made, it should be
possible to solve the academic problems of the young investigator associated with such trials.
Richard D. Remington, Ph.D. Ann Arbor, Mich.
University of Michigan School of Public Health
I have been asked to discuss some of the
problems faced by university faculty members
who participate in clinical trials. I take this as-
signment to be limited to those problems di-
rectly related to the academic condition. Now,
what is that academic condition? Faculty mem-
bers entering an academic environment must
engage in teaching, research, and service. They
look forward to regular merit increases, to pro-
motion, to the acquisition of academic tenure,
and to the establishment of a professional and
scientific reputation outside the institution in
which they serve.
Time commitments
Many academic institutions will suggest an
appropriate allocation of time to teaching, re-
search, and service. The institution for which I
am administratively responsible (the University
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of Michigan School of Public Health) suggests
as a guideline that a faculty member should
normally devote 40% of his time to teaching,
40% to research, and 20% to university, com-
munity, or professional service. Gur school
conducts a quantitatively oriented annual re-
view designed to determine whether or not a
given faculty member has performed at a level
of quantity and quality consistent with estab-
lished norms in each of these three areas. That
evaluation is used to provide merit increases
each year. A relatively elaborate system for
promotion and the acquisition of tenure is in
place within the schoo\.
This system is based on review by tenured
faculty within the department, and recommen-
dation for promotion is then made to the Dean
and Executive Committee. The recommenda-
tion and all documentation, including outside
peer evaluation, are forwarded to an Advisory
Committee on Academic Rank which then
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makes a recommendation to the Dean and Ex-
ecutive Committee for final transmission and
ratification by the Board of Regents of the Uni-
versity.
Perhaps most academic institutions follow a
roughly similar system. We encourage faculty
members to participate in community service
projects which will take them beyond their
academic discipline as narrowly defined. We
believe this is good for the school, for the uni-
versity, and for the individual faculty member.
After all, the development of an academic and
scholarly reputation is important to any young
scientist. We are not interested in establishing
an indentured class of faculty members who are
not in demand by other academic institutions.
Furthermore, we believe that there exists a
healthy degree of mobility and that not every
faculty member will decide to remain within his
or her department throughout a professional
lifetime. Of course, we do not encourage mo-
bility for mobility' s sake alone.
Participation in a clinical trial
Now let us examine briefly the environment
of the cooperative clinical trial. Whether within
the context of a clinical center, a coordinating
center, or a specialized data evaluation center
such as a biochemistry laboratory or an electro-
cardiographic monitoring center, certain charac-
teristics and requirements of a collaborati ve
clinical trial are relevant to investigator partici-
pation. First, publication of results is ordinarily
rigidly controlled by the apparatus of the trial,
and there will be many more potential authors
than publication opportunities. In a trial of rea-
sonable duration a given young investigator will
find it difficult to have his name individually
associated with a large number of publications.
Of course, rules vary and it may weil be possi-
ble by policy for such investigators to list in
their bibliographies all publications resulting
from the collaborative trial with which they are
associated. In some instances, however, this is
not possible and in others a few scientists en-
gaged in preparing an individual manuscript
will be credited by name.
Second, the conduct of a collaborative re-
search project requires adherence to a study de-
sign, protocol, and manual of operation. These
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documents will result from negotiations among
senior scientists responsible for the initial de-
sign of the trial. This activity constitutes one of
the greatest intellectual challenges within the
trial as a whole. Thus, a young investigator
must conform to a considerable degree to the
restrictions implicit in the design and protocol.
This produces a limitation on his ability to
exercise independent intellectual judgment.
Against these problems, one must set the un-
deniable advantage to the faculty member of
becoming acquainted with a large, cosmopoli-
tan group of investigators located at a number of
institutions. This arrangement can provide use-
ful professional contacts and may even lead to
future employment opportunities.
Reviewing groups and advisory boards have
an important impact on the personal participa-
tion of academic investigators in clinical trials.
Reviewers of contract and grant proposals will
often expect individuals to devote a substantial
amount oftime to a collaborative trial. After all ,
the trial is important to the funding agency, to
the reviewers who have devoted important time
to providing an evaluation of the application,
and to policy advisory boards and other groups
who have made a similar time commitment.
The reviewing groups can thus be expected to
require a substantial investment of time from a
number of investigators associated with the
project.
At one institution where I served as Associate
Dean for Research, it was our uniform practice
in dealing with this latter problem to point out to
funding agencies and reviewing bodies that, by
school policy, a faculty member was ordinarily
permitted to spend up to 40% of his time in
research. Thus a 20% total time commitment
amounted to a 50% total research obligation.
This institution's record at securing funding for
its grants and contracts was good, and I am
unaware that this policy ever resulted in a dis-
approval or a low priority rating of one of our
applications. I believe the forthright statement
of institutional policy as apart of each applica-
tion ~ay have been helpful in this connection.
How should we, as senior professors and
administrators, advise our young faculty col-
leagues concerning their potential participation
in cooperative clinical trials? On the one hand,
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the opportunity to associate with colleagues in
comparable institutions is undeniably valuable.
The excitement of being engaged in important
public research which can have a major
influence on therapeutic practice is consider-
able. The excitement of participating in the
group process that leads to collective decisions
is stimulating and informative. The experience
gained in associating with a collaborative proj-
ect is inherently maturing; yet these benefits are
not without cost. Promotions committees, ex-
ecutive committees, and deans expect to see
evidence of a young investigator's intellectual
independence and maturity before they recom-
mend promotion or appointment to a tenured
position. Occasionally, affiliation with a coop-
erative trial can provide such evidence. More
often, however, even the participants in such a
trial will have difficulty providing an objective
assessment of the independent, individual con-
tribution of a given person. Group processes are
inherently complex, and interactions are often
as important in determining outcomes as indi-
vidual actions.
Occasionally, a young investigator will be
able to affiliate hirnself with an ancillary or
spin-off project away from the main line of in-
vestigation. In this event, he may be able to
receive substantial promotion points for that ac-
tivity. More often, however, it will be difficult
for a young faculty member to receive appro-
priate credit for the massive investment of time
required in the conduct of a cooperative trial.
Thus, it seems to me that we have an obligation
to warn the potential young collaborator who is
about to affiliate with a clinical trial that he can
simply not expect full reward for such partici-
pation in terms of prornotion , tenure, and the
like. My advice is, therefore , that young inves-
tigators should not commit a major fraction of
their investigative time to a cooperative clinical
trial. Certainly, I am very wary of assigning a
young person a full-time responsibility to such
an effort. An exception may be the full-time
assignment of an individual for a year or two ,
with the understanding that such experience
may weil be consistent with the individual' s ul-
timate career goals and that he will, after the
experience with the cooperative trial, move on
to other activities in which such a major time
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commitment to such a relatively unrewarding
environment will not be necessary.
Possible accommodations
Do such personnel difficulties constitute in-
surmountable barriers to the success of a
cooperative clinical trial, and do they produce
irreconcilable differences? I think not. I believe
we should not expect young academics to de-
vote over many years most of their time to clini-
cal trials. We should encourage them to engage
in independent scholarly activity, more likely to
contribute to academic advancement. Should
we attempt to alter promotion and tenure
policies in our academic institutions? We can do
so if we wish, but I suspect that, at least in the
major research universities , we will not often be
successful. Furthermore, I must question the
values intrinsic in such an effort. Independent
scholarship is still valuable, although I am per-
sonally a believer in collaborative research. An
analysis we conducted of authorship practices in
a wide variety of scientific journals a few years
ago suggests an increasing trend, even in the
so-called basic sciences , toward multiauthored
papers and away from single authorship. Our
practice at Michigan is to count coauthorships at
full weight with solo authorships, at least as far
as merit increases are concerned. I suspect that
promotion and tenure committees, on the other
hand, will continue to place some emphasis on
individually authored contributions.
Does this mean that academic and scientific
staffs associated with cooperative clinical trials
should be drawn either from nonacademic in-
stitutions or from nonresearch-oriented univer-
sities? It does not. I personally believe that,
with appropriate compromises between the
management of the trial and the management of
the institution, an accommodation can almost
always be effected. As an administrator, how-
ever, I operate by the principle that the
academic administration must take pains to
avoid entrapment of young faculty members.
(The administration should help young faculty
avoid entrapment by others, as weil.) On the
contrary, the acadernic administrator should ac-
cept the challenge of urging senior faculty to
contribute to the development of junior aca-
dernie colleagues. The administrator should
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seek an environment in which reasonable career
goals can be attained by assistant professors and
instructors. This encouragement of junior mem-
bers of the faculty clearly benefits the institution
and also the individual faculty member.
I am aware of the fact that some academic
departments have devoted a substantial fraction
of their total effort to collaborative research. I
believe that this arrangement can be suitable,
provided that this policy does not work a dis-
service to junior faculty _ Indeed, the presence
of an active collaborative trial or its coordinat-
ing center in the academic department can
create an environment in which opportunities
for independent scholarship will be promoted
rather than inhibited. This seems particularly
true in methodologie areas such as epidemiol-
ogy and biostatistics. Certainly, there is no
University-based scientists and clinical trials 665
shortage of challenging design, management,
and analytic problems arising from collabora-
tive research that can require the development
of new methodology.
Finally, I believe we should all pool our
thinking and attempt to develop innovative so-
lutions to the problems faced by the young in-
vestigator in collaborative research. Inciden-
tally, although I have focused on the young,
these problems exist in one form or another for
investigators of all ages. I believe that with a
large dose of good will and some incisive think-
ing we can fund, organize, and administer
cooperative trials in a manner that gives in-
creased attention to the academic problems
faced by the university investigator affiliated
with a long-term cooperative project.
